全文获取类型
收费全文 | 12232篇 |
免费 | 570篇 |
国内免费 | 101篇 |
专业分类
耳鼻咽喉 | 90篇 |
儿科学 | 250篇 |
妇产科学 | 150篇 |
基础医学 | 1376篇 |
口腔科学 | 220篇 |
临床医学 | 689篇 |
内科学 | 3538篇 |
皮肤病学 | 349篇 |
神经病学 | 820篇 |
特种医学 | 364篇 |
外科学 | 1970篇 |
综合类 | 52篇 |
预防医学 | 350篇 |
眼科学 | 152篇 |
药学 | 640篇 |
中国医学 | 45篇 |
肿瘤学 | 1848篇 |
出版年
2023年 | 76篇 |
2022年 | 46篇 |
2021年 | 222篇 |
2020年 | 140篇 |
2019年 | 187篇 |
2018年 | 282篇 |
2017年 | 196篇 |
2016年 | 251篇 |
2015年 | 273篇 |
2014年 | 378篇 |
2013年 | 408篇 |
2012年 | 733篇 |
2011年 | 813篇 |
2010年 | 466篇 |
2009年 | 369篇 |
2008年 | 790篇 |
2007年 | 856篇 |
2006年 | 782篇 |
2005年 | 849篇 |
2004年 | 860篇 |
2003年 | 878篇 |
2002年 | 825篇 |
2001年 | 150篇 |
2000年 | 113篇 |
1999年 | 158篇 |
1998年 | 170篇 |
1997年 | 125篇 |
1996年 | 145篇 |
1995年 | 153篇 |
1994年 | 141篇 |
1993年 | 99篇 |
1992年 | 98篇 |
1991年 | 104篇 |
1990年 | 70篇 |
1989年 | 68篇 |
1988年 | 64篇 |
1987年 | 46篇 |
1986年 | 40篇 |
1985年 | 55篇 |
1984年 | 63篇 |
1983年 | 42篇 |
1982年 | 51篇 |
1981年 | 52篇 |
1980年 | 19篇 |
1979年 | 32篇 |
1978年 | 17篇 |
1977年 | 15篇 |
1976年 | 10篇 |
1975年 | 17篇 |
1973年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Clinical Rheumatology - 相似文献
2.
Takafumi Koyama Toshio Shimizu Satoru Iwasa Yutaka Fujiwara Shunsuke Kondo Shigehisa Kitano Kan Yonemori Akihiko Shimomura Sakura Iizumi Tatsuya Sasaki Junji Furuse Noboru Yamamoto 《Cancer science》2020,111(2):571-579
Fibroblast growth factor receptors (FGFR) are a family of transmembrane receptor tyrosine kinases involved in regulating cellular processes. FGFR mutations are implicated in oncogenesis, representing therapeutic potential in the form of FGFR inhibitors. This phase I, first‐in‐human study in Japan evaluated safety and tolerability of E7090, a potent selective FGFR1‐3 inhibitor, in patients with advanced solid tumors. Dose escalation (daily oral dose of 1‐180 mg) was carried out to assess dose‐limiting toxicity (DLT), maximum tolerated dose, and pharmacokinetics. Pharmacodynamic markers (serum phosphate, fibroblast growth factor 23, and 1,25‐(OH)2‐vitamin D) were also evaluated. A total of 24 patients refractory to standard therapy or for whom no appropriate treatment was available were enrolled. No DLT were observed up to the 140‐mg dose; one patient in the 180‐mg cohort experienced a DLT (increased aspartate aminotransferase/alanine aminotransferase, grade 3). The maximum tolerated dose was not reached. Dose‐dependent increases in the maximum concentration and area under the curve from time 0 to the last measurable concentration were observed up to 180 mg. Dose‐dependent increases were observed in all pharmacodynamic markers and plateaued at 100‐140 mg, indicating sufficient FGFR pathway inhibition at doses ≥100 mg. In conclusion, E7090 showed a manageable safety profile with no DLT at doses ≤140 mg. Maximum tolerated dose was not determined. The recommended dose for the follow‐up expansion part, restricted to patients with tumors harboring FGFR alterations, was determined as 140 mg, once daily. 相似文献
3.
Shinichi Tsuruta Kenichi Kohashi Yuichi Yamada Minako Fujiwara Yutaka Koga Eikichi Ihara Yoshihiro Ogawa Eiji Oki Masafumi Nakamura Yoshinao Oda 《Cancer science》2020,111(3):1008-1019
ARID1A, one of the subunits in SWI/SNF chromatin remodeling complex, is frequently mutated in gastric cancers with microsatellite instability (MSI). The most frequent MSI in solid‐type poorly differentiated adenocarcinoma (PDA) has been reported, but the SWI/SNF complex status in solid‐type PDA is still largely unknown. We retrospectively analyzed 54 cases of solid‐type PDA for the expressions of mismatch repair (MMR) proteins (MLH1, PMS2, MSH2, and MSH6), SWI/SNF complex subunits (ARID1A, INI1, BRG1, BRM, BAF155, and BAF170) and EBER, and mutations in KRAS and BRAF. We analyzed 40 cases of another histological type of gastric cancer as a control group. The solid‐type PDAs showed coexisting glandular components (76%), MMR deficiency (39%), and complete/partial loss of ARID1A (31%/7%), INI1 (4%/4%), BRG1 (48%/30%), BRM (33%/33%), BAF155 (13%/41%), and BAF170 (6%/2%), EBER positivity (4%), KRAS mutation (2%), and BRAF mutation (2%). Compared to the control group, MMR deficiency and losses of ARID1A, BRG1, BRM, and BAF155 were significantly frequent in solid‐type PDAs. Mismatch repair deficiency was associated with the losses of ARID1A, BRG1, and BAF155 in solid‐type PDAs. In the MMR‐deficient group, solid components showed significantly more frequent losses of ARID1A, BRG1, BRM, and BAF155 compared to glandular components (P = .0268, P = .0181, P = .0224, and P = .0071, respectively). In the MMR‐proficient group, solid components showed significantly more frequent loss of BRG1 compared to glandular components (P = .012). In conclusion, solid‐type PDAs showed frequent losses of MMR proteins and the SWI/SNF complex. We suggest that loss of the SWI/SNF complex could induce a morphological shift from differentiated‐type adenocarcinoma to solid‐type PDA. 相似文献
4.
5.
High prevalence of toothache among Great East Japan Earthquake survivors living in temporary housing
6.
7.
8.
9.
10.
Yutaka Fujioka Nobuhiro Hata Ryusuke Hatae Satoshi O. Suzuki Yuhei Sangatsuda Yukiko Nakahara Masahiro Mizoguchi Koji Iihara 《Neuropathology》2020,40(1):99-103
Diffuse midline glioma, H3 K27M mutant arises from midline structures of the central nervous system and predominately affects pediatric patients. However, this disease entity was only recently established, and the clinical phenotypic spectrum remains largely unclear. We herein report a rare case of diffuse midline glioma, H3 K27M mutant with an unusual distribution in an elderly woman who presented with a diffuse glioma that invaded both sides of the thalami, and left hippocampus and frontoparietal lobes, thus mimicking a hemispheric malignant glioma. A biopsy of the lobular lesion led to a molecular diagnostic confirmation of diffuse midline glioma, H3 K27M mutant. The patient received concurrent bevacizumab and temozolomide therapy with radiation therapy and survived for 30 months. This case highlights the possibility that a glioma with cerebral hemispheric spread in an elderly patient may harbor the H3 K27M mutation. 相似文献